ExodusPoint Capital Management LP Acquires Shares of 47,840 CRISPR Therapeutics AG (NASDAQ:CRSP)

ExodusPoint Capital Management LP bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 47,840 shares of the company's stock, valued at approximately $1,883,000. ExodusPoint Capital Management LP owned about 0.06% of CRISPR Therapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in CRSP. The Manufacturers Life Insurance Company grew its stake in CRISPR Therapeutics by 1.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after buying an additional 231 shares during the last quarter. State Street Corp grew its position in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after purchasing an additional 599,304 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock worth $47,383,000 after purchasing an additional 35,196 shares during the period. Sunbelt Securities Inc. lifted its holdings in CRISPR Therapeutics by 11.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company's stock worth $139,000 after purchasing an additional 300 shares during the last quarter. Finally, Sanctuary Advisors LLC boosted its stake in CRISPR Therapeutics by 17.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company's stock valued at $398,000 after purchasing an additional 1,258 shares during the period. Institutional investors own 69.20% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CRSP shares. Citigroup dropped their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a report on Tuesday, February 18th. Barclays boosted their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Truist Financial increased their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. Royal Bank of Canada dropped their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a research report on Wednesday, February 12th. Finally, Morgan Stanley increased their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a research report on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $73.11.

CRISPR Therapeutics Trading Down 1.0 %

Shares of CRSP stock traded down $0.41 on Monday, hitting $38.89. 533,662 shares of the stock were exchanged, compared to its average volume of 1,620,961. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $67.88. The firm's 50 day moving average is $41.14 and its two-hundred day moving average is $44.01. The firm has a market capitalization of $3.34 billion, a PE ratio of -8.90 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. The trade was a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock valued at $1,608,243 in the last three months. Company insiders own 4.10% of the company's stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.